These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27181498)

  • 1. Managing non-alcoholic fatty liver disease in diabetes: Challenges and opportunities.
    Lee CH; Lam KS
    J Diabetes Investig; 2017 Mar; 8(2):131-133. PubMed ID: 27181498
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of patients with non-alcoholic steatohepatitis (NASH) in real life.
    Serfaty L
    Liver Int; 2018 Feb; 38 Suppl 1():52-55. PubMed ID: 29427486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.
    Ferguson D; Finck BN
    Nat Rev Endocrinol; 2021 Aug; 17(8):484-495. PubMed ID: 34131333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital.
    Marjot T; Sbardella E; Moolla A; Hazlehurst JM; Tan GD; Ainsworth M; Cobbold JFL; Tomlinson JW
    Diabet Med; 2018 Jan; 35(1):89-98. PubMed ID: 29094442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fighting the fatty liver.
    Drew L
    Nature; 2017 Oct; 550(7675):S102-S103. PubMed ID: 29019968
    [No Abstract]   [Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease and diabetes.
    Reyes-García R; Rozas-Moreno P; Llamoza-Torres CJ; Mezquita-Raya P
    Med Clin (Barc); 2017 Jan; 148(1):33-38. PubMed ID: 27751514
    [No Abstract]   [Full Text] [Related]  

  • 7. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
    Sberna AL; Bouillet B; Rouland A; Brindisi MC; Nguyen A; Mouillot T; Duvillard L; Denimal D; Loffroy R; Vergès B; Hillon P; Petit JM
    Diabet Med; 2018 Mar; 35(3):368-375. PubMed ID: 29247558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement.
    Citrome L; Volavka J
    J Clin Psychiatry; 2005 Aug; 66(8):1073-4. PubMed ID: 16086627
    [No Abstract]   [Full Text] [Related]  

  • 9. [French CCAFU guidelines on prostate cancer: hormono-naive metastatic prostate cancer - update 2017].
    Rozet F; Hennequin C; Mongiat-Artus P; Beuzeboc P; Beauval JB; Cormier L; Fromont-Hankard G; Ouzzane A; Ploussard G; Renard-Penna R; Méjean A
    Prog Urol; 2018 May; 28(6):303-306. PubMed ID: 29680190
    [No Abstract]   [Full Text] [Related]  

  • 10. An update on nonalcoholic fatty liver disease.
    Provencher DM
    JAAPA; 2014 Jul; 27(7):18-22. PubMed ID: 24901731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using a low-carbohydrate diet to treat obesity and type 2 diabetes mellitus.
    Westman EC; Yancy WS
    Curr Opin Endocrinol Diabetes Obes; 2020 Oct; 27(5):255-260. PubMed ID: 32740047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An interpretation of European guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease].
    Xin FZ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):403-5. PubMed ID: 27465941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of clinical practice guidelines should not be overestimated.
    Lember M; Rätsep A; Kalda R; Oja I
    J Am Board Fam Pract; 2004; 17(6):474-5; author reply 475. PubMed ID: 15575042
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetes update: Your guide to the latest ADA standards.
    Johnson E; Warren F; Skolnik N; Shubrook JH
    J Fam Pract; 2016 May; 65(5):310-8. PubMed ID: 27275934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In focus: adiposity]].
    Klauser A
    Internist (Berl); 2006 Aug; 47(8):870; author reply 870-1. PubMed ID: 16998960
    [No Abstract]   [Full Text] [Related]  

  • 16. [In focus: adiposity].
    Kessler R
    Internist (Berl); 2006 Aug; 47(8):871; author reply 871. PubMed ID: 16998961
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Borodavkin P; Sheridan W; Coelho C; Oštarijaš E; Zaïr ZM; Miras AD; McGowan B; le Roux CW; Vincent RP; Dimitriadis GK
    Diabetes Obes Metab; 2022 Feb; 24(2):337-342. PubMed ID: 34605124
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-life Perception and Practice Patterns of NAFLD/NASH in Romania: Results of a Survey Completed by 102 Board-certified Gastroenterologists.
    Iacob S; Ester C; Lita M; Ratziu V; Gheorghe L
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):183-9. PubMed ID: 27308649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 receptor agonists in NAFLD.
    Petit JM; Vergès B
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-alcoholic fatty liver: position document of the Catalan Society of Gastroenterology].
    Caballería L; Saló J; Berzigotti A; Planas R; Vila C; Huertas C; Torres M; Torán P; Caballería J;
    Gastroenterol Hepatol; 2014; 37(6):372-83. PubMed ID: 24746904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.